^
CD20 expression
B Acute Lymphoblastic Leukemia
rituximab
Sensitive
:
C3
SOHO 2022 - 6 days - (New C3)
No biomarker
B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive
:
A1
No biomarker
Childhood B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive
:
A1
CD22 positive
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive
:
A1
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive
:
A1
No biomarker
Childhood B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive
:
A1
CD19 positive
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
brexucabtagene autoleucel
Sensitive
:
A1
CD20 positive
Childhood B Acute Lymphoblastic Leukemia
rituximab
Sensitive
:
A1
PDGFRA fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive
:
A2
ABL2 fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive
:
A2
FGFR fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive
:
A2
IL7R mutation
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive
:
A2
SH2B3 alteration
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive
:
A2
CRLF2 rearrangement + JAK2 fusion
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive
:
A2
EPOR rearrangement
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
imatinib
Sensitive
:
A2
ABL1 fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive
:
A2
JAK2 fusion
Childhood B Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive
:
A2
PDGFRB fusion
Childhood B Acute Lymphoblastic Leukemia
dasatinib
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cytarabine + cyclophosphamide + vincristine + methotrexate + pegaspargase
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
vincristine + mitoxantrone + dexamethasone + pegaspargase
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + nelarabine
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
imatinib
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cyclophosphamide + etoposide oral + clofarabine
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
dasatinib
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
bortezomib
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
Tyrosine kinase inhibitor
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
bosutinib
Sensitive
:
A2
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
nilotinib
Sensitive
:
A2